- Home
- AVTX vs CLPR Comparison
AVTX vs CLPR Comparison
Compare AVTX & CLPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- CLPR
- Stock Information
- Founded
- AVTX 2011
- CLPR 2015
- Country
- AVTX United States
- CLPR United States
- Employees
- AVTX N/A
- CLPR N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- CLPR Real Estate Investment Trusts
- Sector
- AVTX Health Care
- CLPR Real Estate
- Exchange
- AVTX Nasdaq
- CLPR Nasdaq
- Market Cap
- AVTX 57.4M
- CLPR 57.8M
- IPO Year
- AVTX 2015
- CLPR 2017
- Fundamental
- Price
- AVTX $4.13
- CLPR $3.83
- Analyst Decision
- AVTX Strong Buy
- CLPR
- Analyst Count
- AVTX 6
- CLPR 0
- Target Price
- AVTX $34.20
- CLPR N/A
- AVG Volume (30 Days)
- AVTX 62.6K
- CLPR 74.4K
- Earning Date
- AVTX 05-12-2025
- CLPR 05-12-2025
- Dividend Yield
- AVTX N/A
- CLPR 10.00%
- EPS Growth
- AVTX N/A
- CLPR N/A
- EPS
- AVTX N/A
- CLPR N/A
- Revenue
- AVTX $441,000.00
- CLPR $152,413,000.00
- Revenue This Year
- AVTX N/A
- CLPR N/A
- Revenue Next Year
- AVTX N/A
- CLPR N/A
- P/E Ratio
- AVTX $0.59
- CLPR N/A
- Revenue Growth
- AVTX N/A
- CLPR 8.63
- 52 Week Low
- AVTX $3.39
- CLPR $3.38
- 52 Week High
- AVTX $16.00
- CLPR $7.12
- Technical
- Relative Strength Index (RSI)
- AVTX 45.63
- CLPR 44.02
- Support Level
- AVTX $3.43
- CLPR $3.84
- Resistance Level
- AVTX $4.03
- CLPR $4.00
- Average True Range (ATR)
- AVTX 0.34
- CLPR 0.12
- MACD
- AVTX 0.09
- CLPR -0.03
- Stochastic Oscillator
- AVTX 70.47
- CLPR 0.00
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.